Change in spleen volume and tumor symptom score from baseline. (A) Waterfall plot of maximum percentage change in spleen volume at any time for patients with baseline splenomegaly treated with tagraxofusp 12 μg/kg per day (ITT population). (B) Waterfall plot of maximum percentage change in tumor symptom score at any time for patients treated with tagraxofusp 12 μg/kg per day (ITT population). ∗Seven patients are not shown as they were not evaluable because they did not undergo magnetic resonance imaging/computed tomography scan assessments postbaseline. No spleen response was observed by abdominal examination in any of these patients. Reduction of the line below left costal margin was observed in 2 patients: −29% and −14% (not clinically relevant). †Seven patients were not evaluable for changes in tumor symptoms because they did not have baseline and/or postbaseline tumor symptom scores.